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Abstract:  Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality. 
Periodic spirometry is often recommended for individuals with potential occupational exposure to respiratory hazards and 
in medical treatment of respiratory disease, to prevent COPD or improve treatment outcome. To achieve the full potential 
of spirometry monitoring in preserving lung function, it is important to maintain acceptable precision of the longitudinal 
measurements, apply interpretive strategies that identify individuals with abnormal test results or excessive loss of lung 
function in a timely manner, and use the results for intervention on respiratory disease prevention or treatment 
modification. We describe novel, easy-to-use visual and analytical software, Spirometry Longitudinal Data Analysis 
software (SPIROLA), designed to assist healthcare providers in the above aspects of spirometry monitoring. Software 
application in ongoing workplace spirometry-based medical monitoring programs helped to identify increased spirometry 
data variability due to deteriorating test quality and subsequent improvement following interventions, and helped to 
enhance identification of individuals with excessive decline in lung function. 
Keywords: Spirometry monitoring, prevention, COPD, longitudinal spirometry. 
INTRODUCTION 
  Chronic obstructive pulmonary disease (COPD) is one of 
the leading causes of morbidity and mortality [1]. COPD 
often profoundly diminishes the affected individual’s quality 
of life. Furthermore, excessive decline in lung function is 
associated with premature functional impairment and 
disability, early retirement from work, and increased 
morbidity and mortality [2-5].
  Fortunately, the severe 
consequence of COPD can be prevented through early 
recognition and effective interventions directed at controlling 
known risk factors, including occupational factors [6-11]. 
  Workplace monitoring of spirometry tests of forced 
expiratory volume in one second (FEV1) and forced vital 
capacity (FVC) is widely accepted as a key step in the early 
(preclinical) recognition of both obstructive and restrictive 
lung diseases [12-15]. Professional recommendations 
emphasize several key steps in achieving the full potential of 
spirometry monitoring in disease prevention. These include: 
(i) maintaining acceptable longitudinal data variability (i.e., 
precision); (ii) applying interpretative strategies that have 
good sensitivity, yet sufficient specificity, to identify   
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individuals who may be at risk of experiencing excessive 
loss of lung function (i.e., those at risk of developing lung 
function impairment); and (iii) using health monitoring 
results, including symptoms, to target and monitor 
intervention [12-17].
 Computer software has the potential to 
assist healthcare providers in achieving these steps and thus 
to help in preserving lung health. 
  In this paper, we describe an easy-to-use visual and 
analytical tool, Spirometry Longitudinal Data Analysis 
software (SPIROLA) [18] designed for use by healthcare 
providers as an aid in spirometry monitoring. We outline 
SPIROLA’s methodology and functions, and present results 
from its application in ongoing monitoring programs. The 
software can be downloaded free of charge from the internet 
[18]. 
METHODOLOGICAL BACKGROUND 
  One of the objectives in spirometry monitoring is to 
characterize the time-related pattern of lung function decline 
in adult individuals. This section describes methods 
SPIROLA uses to identify individuals whose decline in lung 
function is greater than expected and the method for 
monitoring longitudinal spirometry data precision and 
quality. 
 FEV1 is the most suitable of the spirometry measures for 
evaluation of lung function changes over time as it is least Spirometry Longitudinal Data Analysis Software  The Open Medical Informatics Journal, 2010, Volume 4    95 
variable within a person, least prone to measurement error, 
and is decreased in both obstructive and restrictive 
impairment. In healthy adult never-smokers with normal 
body weight, FEV1 declines at about 27 ml/yr, starting at 
around 27 years of age, and the decline appears to be linear 
over the working lifetime [19, 20]. The decline with age can 
be estimated using a simple linear regression model, 
FEV1=a+bage, where the slope b represents the rate of 
FEV1 change (e.g., in milliliters per year, ml/yr) [19]. 
  The variability of longitudinal FEV1 measurements 
around the predicted line determines the precision of the 
estimated rate of decline b and is measured by its standard 
error S.E.(b) estimated as [21]: 
S.E.(b)= w 12(P1) /tP (P+1)            (1) 
where  t is the duration of follow-up in years, w is the 
within-person standard deviation and P is the number of 
equally spaced repeated measurements done during the 
follow-up. Fig. (1) shows the estimated values for S.E. (b) 
[using equation (1)] for four individuals with varying 
inherent within-person variation (from low 50 to high 250 
ml), for increasing years of follow-up. The solid line is based 
on  P=2, i.e., baseline comparison with a test taken at a 
specific year, and the dotted line is based on P=t, i.e., all 
annual measurements. The one-sided upper 95% confidence 
limit (95% UCL) for the person’s rate of decline measured 
by the slope b is calculated as (95% UCL)=b+1.645 S.E.(b). 
Depending on the magnitude of individual’s within-person 
variation, it generally takes 5 or more years to estimate an 
individual’s “true” rate of decline with sufficient precision. 
 
Fig. (1). Decline in S.E. (b) in relation to follow-up time and 
varying within-person variation w .  Solid line is based on P=2 
(i.e., baseline and a measurements at a specific year), dotted line is 
based on P=number of years. 
 Fig.  (1) demonstrates that in prospectively collected 
spirometry data where testing is done on an annual or less 
frequent basis as in spirometry monitoring, the slopes 
provided by the linear regression model during the first five 
to eight years, depending on individual’s within-person 
variation, are generally imprecise and may not provide a 
reliable estimate of the “true” rate of decline [21-24]. 
Nevertheless, during this early period there is a need to 
determine whether a person’s observed decline in lung 
function exceeds what would be expected based upon an 
expected rate of decline and expected FEV1 variability. The 
American Thoracic Society (ATS) recommends a limit of 
annual decline for FEV1  of 15% as clinically significant 
decline [25]. The American College of Occupational and 
Environmental Medicine (ACOEM) has proposed a 
longitudinal reference limit based on a 15% annual FEV1 
decline for working populations [14, 15]. However, the fixed 
limit of 15% is too wide for maintaining acceptable data 
precision in a relatively healthy workforce, and too 
insensitive to detect acute adverse effects in some workplace 
situations where excessive decline over a short period of 
time has been observed (see below) [22, 23, 26]. 
 Alternatively,  the  limit of longitudinal decline (LLD) that 
approximates the one-sided upper 95% CL for a referent rate 
of decline and that takes into account the monitoring 
program’s average FEV1 within-person variation has been 
proposed for the evaluation of longitudinal changes in 
individuals [22, 23]. LLDa represents the absolute limit for 
the maximal decline over time t and is defined as follows: 
LLDa=t (b+1.645 S.E.(b))              (2) 
where  b is a referent rate of decline and S.E.(b) is the 
standard error of b as described in equation (1). Since the 
within-person variation w in equation (1) is usually 
unknown for an individual during the early years of follow-
up, one can approximate w by the monitoring program’s 
average within-person standard deviation; this can be 
estimated on a group of n individuals, by the pair-wise 
within-person standard deviation sp as: 
sp =
1
2n
(FEV11i FEV12i)
2
i=1
n
 ,              (3) 
where FEV11i and FEV12i are FEV1 measurements repeated 
approximately one year apart in an ith individual, as done for 
annual spirometry monitoring.
 
 Alternatively,  a  relative limit of longitudinal decline, 
LLDr, for percent decline from the baseline value FEV1 can 
be calculated using equation (1) with the parameters 
standardized by baseline FEV1baseline as b/FEV1baseline and 
S.E.(b/FEV1baseline), where the relative pair-wise within-
person variation sr calculated as: 
sr =
1
2n
FEV11i FEV12i
(FEV11i +FEV12i)/2

 

 
2
i=1
n
            (4) 
is substituted for w  in equation (1). The LLDr limit has 
better applicability for groups that vary with respect to 
gender, height, race, or ethnicity (i.e., factors that affect 
FEV1 size) [23]. Alternatively, published estimates of within-
person variation can be used [23]. 
  The LLD method has been proposed for the purposes of 
maintaining longitudinal data precision in workers’ 
populations and identifying workers who may experience 
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excessive decline during the early (1-8) years of follow-up 
[22, 23]. If an individual’s FEV1 decline exceed the LLD 
limit, a first step in the evaluation should include increase in 
precision of the longitudinal measurements by review of data 
quality or re-testing in near future, before further steps are 
taken. Generally, after 5 to 8 years of follow-up, the 
individual’s own regression slope reaches sufficient 
precision and can be used for decision-making [21-24]. 
 Fig.  (1) demonstrates that for a monitoring program to be 
effective at timely identification of excessive decline in lung 
function and at disease prevention, it is important to maintain 
acceptable precision of the longitudinal measurements. 
Monitoring the program’s absolute and relative pair-wise 
within-person variation statistic sr or sp helps to maintain 
longitudinal data precision at an acceptable level [16]. In 
addition, monitoring test quality grades assigned by a 
spirometer at a testing session can help to monitor 
percentage of tests that do not adhere to ATS/ European 
Respiratory Society (ERS) recommendations. Monitoring of 
precision or test quality grades, overall and by a spirometry 
technician, allows prompt investigation into the source of 
increased variation (e.g., instrument malfunction, procedural 
errors, effects of exposure, technician related errors) [16, 
27]. 
SOFTWARE METHODS AND FUNCTIONS 
Development and Testing 
  From the onset of its development in 2005, SPIROLA 
software has been piloted by several large ongoing 
monitoring programs. In these programs SPIROLA is used 
by physicians and their needs were considered in its 
development. In one program, an Occupational Medicine 
Inc.
® (OMI) spirometry system automatically loads 
spirometry results into SPIROLA to be displayed at the time 
of individuals’ medical examinations. 
Software Environment and Data Requirement 
  SPIROLA runs on PC with Microsoft Windows   
system and requires  Microsoft Windows 2000/XP/Vista, 
Microsoft.NET Framework 2.0 and Database engine, which 
are Microsoft default options. The User Manual, provided by 
the Help menu, describes installation procedure, data input, 
functions, and theoretical background on which the data 
analysis is based. The SPIROLA databases should be kept in 
a secured folder and use a shared folder if multiple users are 
using the data. 
  At a minimum, SPIROLA requires the following data: a 
unique personal identifier, age, height, race/ethnicity, best 
FEV1 and FVC test values, and date of test. Where the 
spirometry system provides quality indices for a testing 
session (i.e., quality grades for acceptability and 
repeatability, second best FEV1 and FVC, technician or 
provider code), these data can be also uploaded into 
SPIROLA database and analyzed by SPIROLA. Data for 
intervention decision-making (e.g., weight, occupational 
exposure factors, smoking data, and questionnaire responses) 
can be included in the database for display in individual 
records. 
  SPIROLA main menu options are easy to operate and 
allow for a spirometry file selection, a group selection and 
evaluation, evaluation of individual’s data, monitoring of 
longitudinal spirometry data precision and tests quality 
scores, and automatic selection of individuals whose tests 
need review because of abnormal findings. 
Functions for Group Evaluation 
  The following functions are provided to assist in 
evaluating data at a group level: 
 (i)  Monitoring longitudinal data precision. To achieve 
and maintain acceptable longitudinal FEV1  data precision 
over time, the program’s data precision is monitored on an 
annual basis using the absolute and relative pair-wise within-
person variation statistics, s p (ml) and sr (%), respectively 
(see Background). 
 (ii) Monitoring the group mean FEV1 and FVC values. 
Time-trends in mean FEV1 and FVC are displayed to help to 
identify effects taking place at a group level (e.g., due to 
occupational hazard, smoking cessation program). To adjust 
for time-related changes in a group’s demographics, 
SPIROLA monitors also the mean predicted values 
estimated from standard or user supplied reference equations 
and z-score. Z-score reflects the mean difference between the 
observed and predicted values expressed in the standard 
deviation units, standardized for demographic data 
distribution. 
 (iii)  Monitoring spirometry quality control. To optimize 
the spirometry quality control for the monitoring program 
and individual technicians, SPIROLA analyzes tests’ quality 
grades assigned by a spirometer at a testing session [28, 29]. 
SPIROLA monitors on a quarterly basis: (i) the percentage 
of tests that do not meet the ATS/ERS criteria for 
acceptability and repeatability, and (ii) the percentage of 
tests that do not meet repeatability criteria (i.e., >150 ml 
between the two best FEV1 and FVC measurements). The 
user can specify quality grades and cutoff points appropriate 
for a spirometer type. 
 (iv)  Screening for individuals with abnormal results. 
Individuals identified to have abnormal lung function results 
are listed in Risk List. Risk List provides summary statistics 
on a number screened and found with specific type of 
abnormal results (see below). 
SPIROLA’s Functions for Individual Evaluation 
  The following functions are provided to assist in 
evaluating data at an individual level: 
 (i)  Evaluating the most recent spirometry test results. As 
recommended by the ATS/ERS and ACOEM, the most 
recent best FEV1, FVC, and FEV1/FVC values are compared 
to U.S. population-based reference values (default) [30] or to 
user-defined reference values [25,28].
  Individuals whose 
values are below the lower limit of normal (LLN, i.e., values 
that have 5% probability of being normal in a healthy non-
smoker population) are identified for further evaluation and 
listed in the Risk List. 
 (ii)  Evaluating longitudinal changes in FEV1.  Time-
trends for FEV1, FVC, and their percent predicted values and 
the FEV1/FVC ratio are displayed graphically. During the 
first seven years of follow-up, SPIROLA applies the limit of 
longitudinal decline (LLD) criterion to identify FEV1 
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measurement(s). The LLD can be specified in absolute 
values (LLDa) or in relative values as percentage (LLDr), or 
as the ACOEM limit; [14,15] a default limit is based on 
within-person variation of 4% [23]. Beginning with the 
fourth year of follow-up, the changes in the rate of FEV1 
decline due to each longitudinal data point are monitored 
graphically. The later function is useful in monitoring the 
effect of intervention or identification of events leading to 
deterioration in the rate of decline. Beginning with eight 
years of follow-up, SPIROLA evaluates whether an 
individual is at risk of developing FEV1 values that has low 
probability of being normal (i.e., <0.1 percentile which is 
comparable to 60% predicted, defined by ATS as moderate 
impairment), based on the level of FEV1 and the rate of FEV1 
decline [31]. 
 (iv)  Evaluating longitudinal FEV1 data variability. 
Within-person variation in FEV1 and FVC is calculated 
when there are three or more longitudinal measurements and 
evaluated for the probability of being normal. 
 (v)  An Individual’s report displays. An individual’s 
report display results of data analyses together with 
demographic data. If there are abnormal findings, the 
individual report suggests steps to be considered in further 
evaluation. These include: (a) assessment of the individual’s 
longitudinal data; obvious outliers can be excluded 
temporarily from the analysis; (b) review of the baseline and 
most recent spirometry tracings and test quality; (c) re-
testing in near future to confirm the results; and (d) only if 
abnormal test results are confirmed, further steps such as 
further medical evaluation and intervention on potential risk 
factors are recommended. 
 (vi)  Tagging individuals for further evaluation. The 
software enables the user to create a list of individuals for 
quality control or re-testing, and intervention. 
  The project proposal and methods were approved by the 
NIOSH Human Subject Review Board. 
RESULTS 
  Results presented are examples from application of 
SPIROLA to data from several ongoing monitoring 
programs. The examples have been selected to demonstrate 
SPIROLA functions and to show how the results can help 
healthcare providers. 
Group Evaluation of Spirometry Data Precision and 
Mean Lung Function Values 
  Application of SPIROLA in 2005 for the evaluation of 
data precision in one of the monitoring programs prompted 
concerns about spirometry quality. Fig. (2, bottom part) 
shows that the annual values of absolute and relative pair-
wise within-person variation, sp (ml) (left axis) and sr (%) 
(right axis), had declined gradually from the program’s 
inception in 1988 until  1999, indicating improving data 
quality, but then the statistics showed a marked increase in 
data variability from 2000. In June 2001, a volumetric 
spirometer, used since 1988, had been replaced by a new 
flow-based spirometer. Data generated by the new 
spirometer resulted in a marked increase in data variability 
since 2000; the year 2000 includes repeated measurements  
 
done in 2001. Prompted by the SPIROLA results, 
interventions to improve spirometry quality was initiated in 
2005 and involved the following measures: technician 
training through a NIOSH-approved spirometry training 
course [32] in April 2005; replacement of a flow-based 
spirometer by a volumetric spirometer in December 2005; a 
computerized central-quality control by a senior technician 
from September 2006; and SPIROLA’s quality grades 
analysis from January 2008. Taken together, the 
interventions resulted in a substantial decrease in the within-
person variation from 2006. The observation in 2008 is 
based on first observations made from after January 2008 
and includes repeated tests made mainly because of quality 
issues. The sr (right axis) value of 4% achieved from 2006-7 
signifies acceptable data precision and corresponds to annual 
LLDr value of 10% [22, 23]. 
 Fig.  (2, top charts) also shows trends for the observed 
(green line) and predicted (yellow line) group mean FEV1 
and FVC values by year. As there were no changes in the 
employment pattern since the intervention onset in 2005, the 
increase in the observed means in relation to the predicted 
means and the increase in the z-scores (red line) was mainly 
due to the improvement in spirometry quality. Charts shown 
in Fig. (2) can be displayed individually also. 
Evaluation of Spirometry Quality Grades 
 Fig.  (3) shows SPIROLA’s chart generated from the 
analysis of quality indices (the grades assigned by a 
spirometer, within-test repeatability, and relative pair-wise 
within-person variation), in this case summarized across all 
technicians, by quartiles. Individual technicians’ charts can 
be also shown.  
  The quality of the FEV1 test was mostly acceptable, 
based on the small percentage of tests that did not meet the 
ATS/ERS criteria of acceptability and repeatability (<10%) 
(green lines ), within-test repeatability (<10%) (blue line 
), and pair-wise within-person variation of 4%
22 (red line); 
a yellow circle indicates small sample size. On the other 
hand, a large percentage of the FVC measurements did not 
meet the ATS/ERS criteria. Additional training in 2008 help 
to improve acceptability of FVC measurements; most of the 
unacceptable tests failed to fulfill the end of test criteria [28].
 
Analysis by technicians permitted specific guidance to 
individual technicians. 
Screening for Individuals with Abnormal Tests Results: 
Risk List 
  The summary results from one monitoring program (Fig. 
4) show that there were 3,449 workers who had at least one 
spirometry test during the screening period. Of these, 312 
(9%) were selected into the risk list because the FEV1/FVC 
ratio was below LLN at the most recent test. Of the 3,084 
individuals who had at least two longitudinal observations, 
174 (5.6%) were selected into the risk list because of 
potential excessive decline: in 102 (3.3%) the excessive 
decline was assessed using LLDr as the duration of follow-up 
was less than 8 years; and in 77 the identification was based 
on the linear regression slope and the risk of developing 
FEV1 value that has <0.1% probability of being normal (i.e., 
moderate impairment). 
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Fig. (2). SPIROLA chart. Upper part shows trends in group FEV1 and FVC means, for the predicted (yellow line), observed (green line) and 
z-scores (red line) values, and bottom part shows absolute (green) and relative (red) pair-wise within-person variation sr or sp, by year. 
 
 
Fig. (3). Percentage of tests that does not meet the ATS/ERS criteria for acceptability and repeatability for FVC (green, ) and FEV1 (green, 
), repeatability (respective blue lines), and relative pair-wise within-person variation sr (red line ), a summary chart by technicians and 
quartiles (yellow triangles indicate a small sample size). 
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Evaluations of Individuals’ Data 
  The first step in the evaluation of individual’s data is to 
view the longitudinal trends. Fig. (5) shows SPIROLA’ 
multiple charts of longitudinal data for FEV1, FVC, and the 
FEV1/FVC ratio for an individual with less than eight years 
of follow-up. Although the most recent lung function values 
were above the LLN (i.e., the lung function level is within 
the normal limits), the FEV1 values are below LLDr from 
35 years of age, indicating excessive decline. There is also 
decreasing trend in FVC. 
 Fig.  (6) shows longitudinal data for an individual with 
eight or more years of follow-up who was identified having 
an excessive decline based on the regression slope and an 
increased risk of development of FEV1 value that has less 
than 0.1% probability of being normal based on the U.S. 
population of healthy nonsmokers (this level corresponds to 
60% predicted, i.e., moderate impairment). 
  The first step in the evaluation is to confirm the results by 
reviewing the longitudinal data, the quality of the baseline 
and last tests, and re-testing if needed to increase 
longitudinal data precision. If an obvious outlier is observed, 
a data point can be temporarily deleted from the analysis. If 
the abnormal findings are confirmed, the individual should 
be referred for further medical evaluation to investigate 
whether there is respiratory abnormality due to a specific 
condition or disease and if needed intervention on potential 
risk factors should be initiated. The results should be 
discussed with an individual to motivate participation in 
interventions directed at controlling occupational and non-
occupational risk factors. Because of confidentiality issues 
individuals’ results should not be made available to the 
employer, only group summary findings should be provided 
to the employer to motivate preventive measures at 
workplace. 
DISCUSSION 
  Periodic spirometry is often recommended for 
individuals with actual and potential exposures to respiratory 
hazards [12-16]. To achieve the full potential of spirometry-
based medical monitoring in detecting the signal due to 
adverse health effects, it is necessary to maintain acceptable 
test quality, and apply interpretive strategies that have high 
sensitivity and specificity in identifying individuals at risk of 
developing lung function impairment. Longitudinal data 
precision determines how soon and how reliably a “true” 
excessive decline can be identified (Fig. 1) [22-23]. 
  SPIROLA software was developed as a visual and 
analytical tool to assist healthcare professionals in 
addressing challenges arising from monitoring respiratory 
health of individuals potentially at risk [18]. The software is 
intended to assist the user in assembling the information 
required to make medical decisions, however, it cannot be 
substituted for competent and informed professional 
judgment.  
  To assist in the evaluation of the practical utility of 
SPIROLA, managers of several ongoing spirometry-based 
health surveillance programs adopted the software. The 
results from monitoring programs conducted on U.S. 
workers reported here demonstrate that the information 
displayed by SPIROLA on longitudinal data precision can 
assist the healthcare professionals to determine potential 
sources of excess variability (e.g., a change in spirometry 
systems and procedural errors) and recognize when an 
intervention on data quality is needed and subsequently, 
whether the intervention improved longitudinal data 
 
Fig. (4). SPIROLA Chart. Summary results from automatic screening for individuals at risk of having abnormal lung function or excessive 
decline in lung function (Risk List). 
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precision (Fig. 2) and quality (Fig. 3). SPIROLA can also aid 
in optimizing the performance of individual technicians 
through the spirometry quality grades analysis (Fig. 3). 
Although appropriate equipment, trained technicians, 
knowledgeable professional oversight, and comprehensive 
procedure manuals are basic components of a quality testing 
program [28], data precision can vary over time for various 
reasons and such changes may not be noticeable on 
individual tests. 
  The estimate of data precision provided by the software 
affords additional benefits during the interpretation of 
longitudinal change for individuals. It facilitates 
determination of an appropriate limit of longitudinal decline, 
LLD, a criterion applied by SPIROLA software to maintain 
longitudinal data precision and detect early (within 8 years) 
excessive lung function decline. The LLD method increases 
flexibility to develop stringent quality control and to increase 
sensitive for detecting long-term excessive decline or acute 
respiratory effects, under different monitoring conditions 
[22, 23]. The knowledge of group longitudinal data precision 
and data quality increases the likelihood of discerning 
whether an observed change in lung function is due to 
procedural error or incipient lung disease. However, 
workplace or environmental factors may be responsible for 
increased FEV1 variability by causing respiratory illness. 
  The user may choose to modify the default parameters on 
which the longitudinal detection limit LLD is based. The 
LLD limit can reflect existing data variability. However, if 
data variability can not be calculated, SPIROLA provides 
LLDr default based on an annual limit of decline of 10 % and 
expected normal physiological lung function decline with 
increasing years. The value of 10% is based on evaluation of 
data precision in several existing monitoring programs, and 
assumes relatively good longitudinal data precision (within-
person variation of 4%) [16, 17, 22, 23]. Alternatively the 
user can use the ACOEM fixed limit [14, 15]. When setting 
the LLDr limit, the user should also consider the severity and 
implications of potential occupational health effects. For 
example, when disabling irreversible work-related excessive 
declines in lung function can occur within short exposure 
duration, as was observed in popcorn workers, higher 
sensitivity is preferable to higher specificity [26].    
  Because COPD is a preventable disease that usually takes 
many years to develop, early recognition of abnormal 
pulmonary function decline followed by an effective 
intervention is important in disease prevention [6].
  The 
longitudinal assessment over all follow-up years based on 
 
Fig. (5). SPIROLA multiple charts for an individual with less than 8 years of follow-up: longitudinal FEV1, FVC and percent predicted 
values plotted against age, and the report summarizing findings. FEV1 is below LLDr from about 35 years of age. 
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evaluation that takes into account data variability, as done by 
SPIROLA, helps to improve the accuracy of recognition of 
development of respiratory disease. By helping to improve 
longitudinal data precision, SPIROLA improves the 
precision of the estimated rate of decline and identification 
of those with true excessive rate of decline. Furthermore, the 
Risk List function helps the healthcare provider to identify 
individuals whose spirometry results may be abnormal and 
who may need further evaluation; this function is especially 
useful in occupational settings where a large number of 
workers undergo spirometry monitoring. 
  A limitation of our study is that the long-term 
implications of the application of SPIROLA for disease 
prevention have not yet been fully evaluated in ongoing 
monitoring programs. Data input can be a limitation that we 
plan to overcome by adding to SPIROLA interfaces to allow 
automatic transfer of spirometry data generated by different 
spirometers. 
CONCLUSION 
  Application of SPIROLA in an ongoing spirometry 
monitoring program has helped to identify previously 
unrecognized increases in longitudinal data variability due to 
equipment and procedural problems, and to demonstrate that 
subsequent data quality interventions resulted in 
improvement in data precision and in spirometry quality. By 
organizing and analyzing longitudinal spirometry data, 
SPIROLA software has helped to improve identification of 
individuals who have or are at risk of developing lung 
function abnormalities. 
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